γ-Aminobutyric acid (GABA) is the primary inhibitory transmitter in the mammalian brain. This inhibition is mediated by type A (GABA A ) receptors that are pentameric proteins assembled from 14 different subunits. While inhibitory synaptic transmission has been studied in the amygdala, the subunit composition of receptors present at different synapses is not well understood. In this study we examined the subunit composition of GABA A receptors at synapses in the basolateral and central amygdala. Using receptors expressed in HEK293 cells we first determined the pharmacology of receptors of different subunit compositions. We then used this pharmacological profile to test the properties of receptors present at synapses in the central and basolateral amygdala. These results show that the GABA A receptor subunits are differentially distributed in the amygdala. Our data indicates that in the basolateral amygdala, GABAergic synapses are likely composed of receptors that contain α1β1/2γ2 subunits. In the central amygdala receptors at the medial input, carrying afferents from the BNST contain similar receptors whereas in the lateral input GABA receptors likely contain γ1 subunits. These inputs arise from the intercalated cells masses, thought to be responsible for mediating extinction of conditioned fear raising the possibility of new targets for the treatment of anxiety related disorders.
Introduction
The amygdaloid complex is a temporal lobe structure that is involved in processing emotional information. In particular, it has a key role in the analysis and expression of fear. Disorders within this complex have been associated with a range of anxiety related disorders such as generalized anxiety, depression and posttraumatic stress.
The treatment of these disorders is complex with both behavioral and pharmacological treatments playing roles. The benzodiazepines form a class of compounds that have potent anxiolytic actions and are often the drug of choice in the first line of treatment for these disorders. These agents produce their therapeutic actions by enhancing the action of GABA at GABA A receptors. Benzodiazepine binding sites are present in the amygdala at high density (Niehoff and Kuhar 1983; Richards and Möhler 1984) and it is likely that the anxiolytic actions of these agents are due to their effects on the amygdala (Pesold and Treit 1994) . However, the physiological actions of benzodiazepines are complicated as these agents have effects on GABA A receptors distributed throughout the central nervous system (Sieghart and Sperk 2002) leading to a range of side effects of systemically administered drugs. Thus, the development of more specific compounds for the treatment of these disorders requires an understanding of the molecular composition of GABA A receptors and their distributions in specific circuits within the amygdala.
The GABA A receptor belongs to the Cys-loop superfamily of ligand-gated ion channel and has a heteropolymeric structure that forms a chloride channel (Barnard et al. 1998; Olsen and Tobin 1990) . Molecular cloning has so far identified 21 different subunits that can assemble to form ionotropic GABA receptors: 6 α, 4 β, 4 γ, 1δ, 1ε, 1π, 1θ, and 3ρ all of which are products of separate genes. Additional heterogeneity is produced by alternative splicing of some of the subunits. These subunits assemble as pentamers and, as for many other ion channels, their biophysical and pharmacological properties are dependent on the subunit stoichiometry (Sieghart and Sperk 2002) . Most GABA A receptors in the mammalian CNS are thought to contain α, β and γ subunits, with the most common receptor having a stoichiometry α1β2γ2 (Mohler 2006; Sieghart and Sperk 2002) . High potency benzodiazepine modulation of the GABA A receptor requires the presence of γ2 subunits (Mohler 2006) . Recent studies have suggested that among the various actions of benzodiazepines, receptors containing α1 subunits are responsible for the sedative/hypnotic actions of benzodiazepines while receptors containing α2 subunits mediate their anxiolytic actions (Rudolph and Mohler 2006) . The amygdaloid complex contains 17 different nuclei that have extensive reciprocal connections with cortical and subcortical regions as well as dense internuclear connections (Sah et al. 2003) . A variety of GABA A receptor subunits are expressed in all nuclei within this complex, and electrophysiological studies both in vivo and in vitro have shown synaptic activation of GABA A receptors in several regions (Delaney and Sah 2001; Lang and Pare 1997; Martina et al. 2001; Royer et al. 1999) . In this paper we have attempted to define the likely subunit composition of GABA A receptors at inhibitory synapses in the central and basolateral amygdala. Using real time PCR we first determine the expression levels of different GABA A receptor subunits. We then measure the pharmacological profile of the most likely receptor combinations by expressing the most abundantly expressed subunit combinations in HEK293 cells. We show that inhibitory synapses in the basolateral amygdala and at synapses formed by medial inputs to neurons in the central amygdala have properties similar to those containing α(1-3)βγ2
subunits. However, a population of receptors present at lateral inputs to CeA neurons appear to contain γ1 subunits.
Methods

Cell culture and transfection
Human embryonic kidney (HEK293) cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% foetal bovine serum and 1% penicillinstreptomycin (Gibco). Cells were harvested once each week and seeded at ~50 % confluence onto glass coverslips in 35 mm culture dishes. Transfections were performed 24 hours after plating.
Rat GABA A receptor α1, α2, β1, γ1 and γ2S subunits were used in this study. The α1 and α2 cDNAs were subcloned into the pcDNA3.1 and pcDNA1.1 plasmid vectors, respectively. The β1 subunit was subcloned into either the pIRES2-EGFP, pCMV-Neo or pcDNA3.1 plasmid vectors. The γ1 and γ2 subunits were subcloned into the pIRES2-EGFP plasmid vector. Cells were transfected using a standard calcium phosphate precipitation protocol. When co-transfecting α and β subunits, the respective cDNAs were combined in a 1:1 ratio, whereas α, β and γ subunits were transfected in a 1:1:3 ratio. After exposure to transfection solution for 24 hrs, cells were washed twice using calcium-free phosphate buffered saline, then returned to standard culture medium until used for recording 24 -72 hrs later.
HEK293 cell electrophysiology
Transfected HEK293 cells were observed using an inverted fluorescent microscope and currents were measured using the whole-cell patch clamp configuration.
Cells were perfused by a control solution that contained 140 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, and 10 mM glucose, with the pH adjusted to 7.4 with NaOH. Patch pipettes were fabricated from borosilicate hematocrit tubing (Vitrex, Modulohm, Denmark) and heat-polished. Pipettes had a tip resistance of 1.5-3 mega-ohms when filled with the standard pipette solution containing 145 mM CsCl, 2 mM CaCl 2 , 2 mM MgCl 2 , 10 mM HEPES, and 10 mM EGTA, with the pH adjusted to 7.4 with NaOH. After establishment of the whole cell configuration, cells were voltageclamped at -40 mV and membrane currents were recorded using an Axopatch 1D amplifier and pClamp 9 software (Axon Instruments, Foster City, CA). The cells were perfused by a parallel array of micro-tubular barrels through which solutions were gravity-induced. Experiments were conducted at room temperature (19 -23 o C).
Real time PCR
All experiments were carried out according to the guidelines of University of Relative expression data was quantified using 2 (Ct sample-Ct b-actin) Where Ct is the cycle threshold. Relative standard curves were generated by plotting the threshold value (Ct) versus the log of the amount of total cDNA added to the reaction and used to check the efficiency of primers. Calculation of Ct, standard curve preparation and quantification of mRNA in the samples were performed by software provided with the Rotor-Gene 3000 (version 6). All target genes were normalized to the β-actin housekeeping gene.
Slice recordings
Wistar rats aged p21 to p28 were anaesthetized with halothane and decapitated. 
Drugs and reagents
Bicuculline methoidide, diazepam, flunitrazepam, zolpidem, DMCM (β-carboline methyl-4-ethyl-6, 7-dimethoxy-β-carboline-3-carboxylate), GABA and kynurenic acid were all obtained from Sigma. Tetrodotoxin (TTX) and 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX) were obtained from Alomone and Tocris Laboratories respectively. Pentobarbitone was a gift from Dr. Mark Bellingham.
Data Analysis
The empirical Hill equation, fitted by a non-linear least squares algorithm (Sigmaplot 9.0, Jandel Scientific, San Rafael, CA), was used to calculate the EC 50 , the IC 50 , and the Hill coefficient (n H ) of excitatory and inhibitory dose-response curves. Statistical significance was determined by a one-way ANOVA with p < 0.05 representing significance.
Results
Functional GABA A receptors present at synapses are thought to be heteromultimers of α, β and γ subunits (Sieghart and Sperk 2002) . To begin to determine the subunit stoichiometry of GABA A receptors present in the amygdala we first mapped expression of different subunits using real time PCR (Fig 1) . These results indicate that in the basolateral amygdala the relative expression levels of GABA A receptor subunits are α2 > α1 β1, β3 >=β2 γ1 < γ2 whereas and in the central amygdala the expression pattern is α2 > α1 β1, β3 >=β2, γ1 > γ2 . As can be seen in 
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GABA sensitivity
From the expression profile of GABA A receptor subunits in the amygdala the different subunit combinations were transiently expressed in HEK293 in a 1:1:3 ratio.
Combinations tested were 〈1®1, 〈2®1, 〈1®1©1, 〈1®1©2, α2®1©1 and 〈2®1©2 GABA A receptors. We first evaluated the GABA sensitivity of each expressed receptor type. Sample current responses from cells expressing α1β1, α2β1 and α2β1γ2 receptors are shown in Fig. 2A and averaged dose-responses for all six receptors are shown in Fig. 2B . Mean parameters of best fit to the individual dose-response curves are presented in Table 1 . In agreement with previous studies on GABA A receptors expressed in Xenopus oocytes (Sigel and Baur 2000; Wafford et al. 1993 ), α1β1 and α2β1 GABA A receptors were significantly (p < 0.01) more sensitive to GABA relative to α1β1γ1, α2β1γ1, α1β1γ2 and α2β1γ2 GABA A receptors. The averaged GABA EC 50 values for the α1β1γ1 and α1β1γ2 GABA A receptors were significantly (p<0.01) reduced relative to those of the α2β1γ1 and α2β1γ2 GABA A receptors. In all pharmacological experiments described below, GABA was applied at the EC 20 concentration at each receptor type. This corresponded to 1 μΜ GABA for 〈1®1 and 〈2®1 receptors, 3 μM GABA for 〈1®1©1 and 〈1®1©2 receptors and 5 μM GABA for α2®1©1 and 〈2®1©2 receptors.
We next tested the effect of bicuculline at all six GABA A receptors. Examples of bicuculline dose-response relationships for α1β1, α2β1γ1 and α2β1γ2 GABA A receptors are shown in Fig. 2B with averaged dose-response relationships for all six receptors plotted in Fig. 2D . The mean parameters of best fit to individual dose-response curves are summarised in Table 1 . Although there was generally a significant increase in bicuculline sensitivity in α2-relative to α1-containing receptors, this difference was too small for use for pharmacologically discriminating among the GABA A receptors investigated here.
Effects of benzodiazepines
The effects of the classical non-selective benzodiazepine receptor agonist, diazepam, were investigated at concentrations between 0.01 to 1000 μM on currents activated by EC 20 GABA at each of the six receptor subtypes. Examples of the diazepam dose-responses at α1β1γ1 and α1β1γ2 GABA A receptors are shown in Fig. 3A , left panel. Diazepam dose-response curves were measured for all receptors with averaged diazepam EC 50 and n H values of best fit summarised in Table 1 . These results agree with previous studies (Pritchett et al. 1989; Walters et al. 2000) showing that γ subunit incorporation conferred a significant increase in diazepam sensitivity. Furthermore, as previously observed in Xenopus oocyte-expressed GABA A receptors (Walters et al. 2000) , 0.1 μM diazepam potentiated γ2-containing receptors to a significantly greater extent than γ1-containing receptors (Fig. 3A, right panel) . As expected, α1β1 and α2β1
receptors were not significantly potentiated by 0.1 μM diazepam. This response profile was largely conserved at 1 μM diazepam, although at 10 μM diazepam the α1β1 and α2β1 GABA A receptors were also strongly potentiated (Fig. 3A, right panel) . These results indicate that diazepam at concentrations of 0.1 -1 μM can be used as a selective pharmacological marker for γ subunit containing GABA A receptors.
The effects of the benzodiazepine type I-selective imidazopyridine, zolpidem (MacDonald and Olsen 1994; Pritchett et al. 1989) , were tested at concentrations of 10 nM to 100 μM on currents induced by EC 20 GABA at each of the six receptors.
Examples of zolpidem effects on α2β1γ1 and α1β1γ2 GABA A receptors are shown in Fig. 3B , left panel. Zolpidem enhanced GABA-induced currents in γ−containing receptors but it had no significant effect on α1β1 or α2β1 receptors at any concentration tested. Thus, dose-response curves for zolpidem were quantitated for γ−containing receptors only, with averaged EC 50 and n H values of best fit summarised in Table 1 . It is apparent in Fig. 3B , right panel, 0.1 and 10 μM zolpidem potentiated α1β1γ2 receptors to a significantly greater extent than α1β1γ1 receptors. Thus, zolpidem can be used to pharmacologically identify the presence of γ subunits and can discriminate between γ1-and γ2-containing GABA A receptors.
DMCM
The β-carboline, DMCM, is an inverse benzodiazepine receptor agonist (Stevenson et al. 1995) . The effects of this compound were tested at concentrations from 1 nM to 10 μM on currents activated by EC 20 GABA at each of the six receptors employed in this study. Examples of the effects of DMCM on α1β1γ1 and α1β1γ2 GABA A receptors are shown in Fig. 3 . DMCM had no consistent effect on α1β1, α2β1, α1β1γ1 or α2β1γ1 GABA A receptors at any concentration (Fig. 3C ).
However, it potently inhibited both the α1β1γ2 and α2β1γ2 GABA A receptorswith IC 50 values in the high nanomolar range (Fig. 3C , Table 1 ). The reduction in GABA-evoked currents at 10 nM was significantly greater for α1β1γ2 receptors than for α2β1γ2
receptors. However, at 1000 nM DMCM, its differential inhibitory effects were largely reduced (Fig. 3C, right panel) . These inhibitory effects of DMCM agree with previous studies (Stevenson et al. 1995) . Studies on oocyte-expressed GABA A receptors have shown a concentration-dependent switch from inverse agonist activity to agonist activity (Sigel et al. 1990; Stevenson et al. 1995) , however, we did not see this effect on receptors expressed in HEK293 cells and DMCM uniformly acted as an antagonist at the receptors we tested (eg Fig. 3C ).
Pharmacology of synaptic GABA A receptors
In agreement with previous studies (Sieghart and Sperk 2002) , Fig. 1 shows that in the basolateral and central amygdala, the dominant subunits expressed are α2
and β3 with α1 expression particularly low in the CeA. Both γ1 and γ2 subunits are also expressed in both nuclei, however, there were clear differences in the expression levels of the two receptors (Fig 1) . In the CeA, relative expression levels of γ1 and γ2 subunits were 803 ± 43 and 560 ± 62 units respectively (p < 0.05, n= 3) where as for the BLA these levels were 342 ± 9 and 1308 ± 25 (p < 0.05, n = 3). Thus, expression of γ1 subunits is significantly higher than γ2 subunits in the CeA whereas the relative levels are reversed in the BLA. Interestingly synaptic GABA A receptors containing γ1 subunits have not been previously described, we therefore tested whether γ1 subunits may be present at synapses in the CeA. We compared the pharmacology of inhibitory synaptic currents at three distinct synapses: those made by local interneurons onto principal IPSCs originating from the medial inputs were almost completely blocked by bicuculline, those activated by lateral inputs were not. When bicuculline was applied at 10 µM, the medially evoked IPSC was blocked to 93 ± 1 % of control (n= 6, p < 0.05) where as the laterally evoked IPSC was only partially blocked (to 64 ± 4 % of control n=6, p < 0.05).
Consistent with the incomplete block of the IPSC at this lateral input, increasing the stimulus intensity in the presence of 10 µM bicuculline increased the amplitude of the laterally evoked IPSC but had no effect on the IPSC evoked from the medial input or the IPSC evoked in the BLA (data not shown).
Effects of benzodiazepines
Diazepam was tested at two concentrations (1 and 10 µM). In the CeA, diazepam
had distinct actions at the medial and lateral input ( Fig. 4A-E) . For the medial input, diazepam at both concentrations had little effect on IPSC amplitude (amplitude 109 ± 14% of control and 112 ± 19 % of control for 1µM and 10 µM respectively; p >0.1, n = 11). The decay time constant of the IPSC was slightly enhanced by 1 µM diazepam (from 41 ± 5 ms to 51 ± 7 ms, p < 0.05) while it was significantly enhanced at 10 µM (to 54 ± 4 ms, p < 0.04, Fig. 4E ). In comparison, the lateral input to CeAL neurons was largely insensitive to diazepam with no effect on either amplitude or decay time constant (Fig. 4B, D, E) . At 1 µM, peak amplitude was 95 ± 10 % of control (p>0.1, n = 11) and the decay time constant changed from 38 ± 4 ms to 40 ± 4 ms (p > 0.1) while 10 µM diazepam caused a led to a modest reduction in peak amplitude 87 ± 10 % of control (p > 0.05, n = 11) and the decay time constant increased to 45 ± 4 ms (p > 0.05, n = 11). In contrast to the CeAL, in the BLA, diazepam enhanced the amplitude of the IPSC at 1 µM (to 139 ± 14 % of control p < 0.01) and slightly slowed the decay time constant from 38 ± 4 ms to 47 ± 6 ms p < 0.05, n=11; Fig. 4C-E) . At 10 µM the amplitude of the IPSC increased to 139 ± 14 % (p < 0.05) but had little further effect on the decay time constant to 50 ± 6 ms (p < 0.05, n=11; Fig 4C-E) .
Zolpidem is a benzodiazepine that potentiates responses to α1-containing receptors to a greater extent than those containing α2 subunits (Korpi et al. 2002; Mohler et al. 2002) . Overall, we found it had similar effects to diazepam ( Fig. 5A-E) . In the CeA, for the medial input the amplitude of the IPSC was little effected by zolpidem at 0.1 µM (to 114± 9 % of control, p > 0.05) but enhanced to 120 ± 9 % of control at 1 µM zolpidem (p < 0.05; n = 7), however, there was minimal effect on the decay time constant decay time constant changing from 39 ± 7 ms to 46 ± 9 ms and 43 ± 7 ms (27%, p > 0.1)
for the low and high concentration respectively (n=9). Similar to the actions of diazepam, at lateral inputs, zolpidem has no effect on the peak amplitude of the IPSC at either low or high concentrations (92 ± 7 % of control at 0.1 µM and 82 ± 2 % of control at 1 µM, p > 0.1, n = 7). The decay time constant was not affected by either concentration of zolpidem (from 33 ± 2 ms to 33 ± 3 ms for 0.1 µM and to 37 ± 2 ms for 1 µM, p > 0.05 for each case, n = 7). In contrast, in the BLA, IPSCs were significantly enhanced. Zolpidem at 0.1 µM increased the peak amplitude of IPSCs to 132 ± 3 % of control (p > 0.05) and the decay time constant was little affected (from 34 ± 4ms to 35 ± 3 ms (p > 0.05) while at 1 µM, zolpidem increased the peak amplitude of IPSCs to 117 ± 5 % of control (p < 0.05) and decay time constant to 40 ± 3 ms (p < 0.05; n=9).
Effect of DMCM
Application of DMCM to IPSCs in the BLA led to a clear reduction in their peak amplitude (Fig. 6) . At a concentration of 10 µM DMCM reduced the peak amplitude to 55 ± 4 % of control (p < 0.01, n = 13) with no effect on the decay time constant (from 55 ± 4 ms to 59 ± 4 ms, n = 13, p > 0.05). In the CeA, application of DMCM reduced the peak amplitude of the medially evoked IPSC by 63 ± 5 % while having no effect on the amplitude of the IPSC evoked by lateral stimulation (IPSC in DMCM 94 ± 16%, n=6, p > 0.05; Fig. 6 ). As in the BLA, DMCM had no effect on the decay time constant of the IPSC at either the medial (control 40 ± 5 ms; DMCM 47 ± 8 ms, n= 11) or the lateral input (control 31 ± 2ms and DMCM 28 ± 2 ms, p > 0.05, n = 9).
DISCUSSION
The amygdala is a temporal lobe structure that plays a key role in emotional behaviour and dysfunction within the amygdala is thought to contribute to a range of anxiety and mood disorders (Davis and Whalen 2001; Drevets 2003) . Benzodiazepines, commonly used as therapeutic agents in the pharmacological management of anxiety related disorders, are well known to act at ionotropic GABA A receptors (Rudolph and Mohler 2006) . However, the therapeutic actions of these agents are complicated by their diverse side effects due to the widespread distribution of GABA A receptors throughout the central nervous system. Because ionotropic GABA A receptors are hetero-oligomeric pentamers that are expressed in different stoichiometries throughout the central nervous system (Sieghart and Sperk 2002) , the design of more specific therapeutic agents requires a clear understanding of the subunit composition of receptors at specific synapses in central circuits. In this study we have attempted to determine the subunit composition of GABA A receptors at inhibitory inputs in the basolateral and central amygdala. Our results show that at GABAergic synapses onto principal neurons in the BLA, the postsynaptic ionotropic receptors that are present are consistent with a composition α1βxγ2. In the lateral sector of the central amygdala, medial inputs, presumably arising from the bed nucleus of stria terminalis contain receptors that are composed of α2βxγ2.
However, lateral inputs, thought to be arising from the intercalated cell masses (Delaney and Sah 2001), express receptors that have a distinctly different pharmacology. While the exact composition of these receptors is currently unclear, our pharmacological analysis suggests that they contain γ1 subunits.
GABA A receptors present at inhibitory synapses in the BLA are potently blocked by bicuculline and are clearly potentiated by both type I and type II benzodiazepines, diazepam and zolpidem, indicating that γ2 subunits are present at these synapses. This is similar to the pharmacology of GABA A receptors that has been described at many synapses in the mammalian central nervous system that are thought to be pentamer containing α1/2β1/3γ2 subunits (Mohler 2006; Sieghart and Sperk 2002) . Consistent with this we find that application of the β-carboline, DMCM, also reduced the amplitude of the IPSC at these synapses. Both mRNA (Fujimura et al. 2005; Pirker et al. 2000) and protein (Marowsky et al. 2004 ) levels of α2 subunits are relatively high in the BLA.
Together with the relatively higher levels of β1 and γ2 subunits, our data suggest that inhibitory synapses on principal neurons in the BLA most likely have a stoichiometry of α2β1/2γ2.
In the lateral sector input of the CeA we have described two different GABAergic inputs to these neurons. One, the 'medial' input, defined by the site of stimulation in acute coronal slices, is thought to originate in the bed nucleus while the 'lateral' input arises from the intercalated neuron masses that form feed forward inhibition between the basolateral and central amygdala (Delaney and Sah 2001) . It should be noted, however, that when stimulating the intercalated cell masses, it is conceivable that our stimulus may spread into the central nucleus to activate local circuit cells within the nucleus. As these local neurons are largely GABAergic, it is possible that some of these inputs originate from local circuits. However, regardless of the origin of these inputs, postsynaptic receptors present at these synapses can be differentiated pharmacologically from those present at medial inputs. Thus, for the medial input, GABA A receptors present at these synapses are potently blocked by bicuculline, are enhanced by both diazepam and zolpidem. Moreover, these receptors are significantly blocked by DMCM. Both mRNA and protein (Kaufmann et al. 2003; Marowsky et al. 2004 ) expression of α2 subunits is relatively high in the CeAL. As both β1/3 as well γ2 subunits are expressed in this nucleus, the most likely receptor composition is α2β1/3γ2, similar to those receptors present at synapses on BLA principal neurons. In contrast, ionotropic GABA receptors present at 'lateral' inputs are less sensitive to bicuculline, and are partially blocked by the benzodiazepines diazepam (Delaney and Sah 1999) and zolpidem (this study).
Moreover, as distinct from receptors at medial inputs, the receptors at these synapses were insensitive to DMCM. γ1 subunits are expressed at higher levels in the CeA (Fig   1) , and receptors assembled with these subunits have a greatly reduced sensitivity to both diazepam and zolpidem and are not affected by DMCM (Fig 3) (Khom et al. 2006) .
These properties are similar to those of receptors present at synapses made by lateral inputs to CeAL neurons. While we cannot reach a definitive conclusion regarding the subunit composition of receptors that are present at these synapses, we suggest that receptors containing γ1 subunits are likely targeted to synapses made by the intercalated neurons onto CeAL neurons.
Most inhibitory synapses in the mammalian CNS are thought to contain αxβxγ2
subunits. Recent studies have suggested that while receptors containing α1 subunits are responsible for the sedative actions of benzodiazepines, α2 subunits are largely responsible for the anxiolytic action of these compounds (Low et al. 2000; Rudolph et al. 1999 ). Our results indicate that GABA receptors present at synapses in both the BLA as well as some synapses in the central amygdala contain both α2 and γ2 subunits. As the amygdala plays a central role in the affective evaluation of emotive events (Davis et al. 1994; Davis and Whalen 2001) , these results indicate that the anxiolytic actions of benzodiazepines (Rudolph and Mohler 2006) are likely mediated by their actions in the amygdala. While γ1 subunits are present throughout the central nervous system (Laurie et al. 1992 ) they are relatively enriched in the central amygdala. However, to our knowledge, functional receptors containing γ1 subunits have not been described in the central nervous system (Mohler 2006) . Our results suggest that synapses made by lateral inputs to neuron in the CeA express receptors containing γ1 subunits. These inputs arise from the intercalated cell masses and are thought to mediate inhibition of amygdala output during extinction of conditioned fear (Likhtik et al. 2008) . Thus, specific modulators of these receptors open the possibility of a selective treatment for anxiety related disorders. EC50 values for each subunit combination are given in Table 1 . Scale bars represent 100 pA and 30s. 2.2 ± 0.4 0.78 ± 0.11 4 zolpidem (nM) α1β1 no effect 5 α2β1 no effect 5 α1β1γ1 182 ± 36 0.90 ± 0.10 5 α2β1γ1 103 ± 21 1.27 ± 0.26 5 α1β1γ2 83 ± 11 1.32 ± 0.36 5 α2β1γ2 64 ± 17 1.45 ± 0.57 6 DMCM (nM) α1β1 no effect 5 α2β1 no effect 6 α1β1γ1 no effect 6 α2β1γ1 no effect 6 α1β1γ2 152 ± 49 -0.35 ± 0.02 5 α2β1γ2 919 ± 267 -0.50 ± 0.08 5 # Values for bicucullne and DMCM represent IC50s, all others represent EC50s. *p < 0.05, **p < 0.01, ***p < 0.001 relative to α1β1 GABA A receptors using one way ANOVA. 
Figure Legends
